Merck: Molnupiravir Shows Consistent Antiviral Activity Agai

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) and Ridgeback Biotherapeutics reported data from six preclinical studies showing that molnupiravir, an investigational oral antiviral COVID-19 medicine,

Related Keywords

Ridgeback Biotherapeutics , Merck Research Laboratories , Merck Research , Merck , Olnupiravir , Shows , Consistent , Antiviral , Activity , Against , Micron , Multiple , Itro , Studies ,